Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for tough pancreatic cancer: targeted drug trial launches

NCT ID NCT07303465

First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 24 times

Summary

This study tests an experimental drug called RNK08954 in 60 adults with advanced pancreatic cancer that has spread and has a specific genetic change (KRAS G12D). The goal is to see if the drug can shrink tumors or slow the cancer's growth, and to check for side effects. Participants will take the drug and be monitored closely over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nanjing Tianyinshan Hospital

    RECRUITING

    Nanjing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai GoBroad Cancer Hospital China Pharmaccutical University

    RECRUITING

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.